Scarica l'app Stockscreener
1.2495
2.48%
0.0395
Telomir Pharmaceuticals Inc Borsa (TELO) Ultime notizie
Telomir Pharmaceuticals (TELO) awards director 50,000 stock options at $1.34 - Stock Titan
Telomir Pharmaceuticals Inc (TELO) Valuation: PE, PB & Fair Value Analysis - TradingKey
TELO|Telomir Pharmaceuticals Inc|Price:1.230|Chg%:+0.080 - TradingKey
Telomir Pharmaceuticals Inc (TELO) Institutional Confidence - TradingKey
Telomir Pharmaceuticals Inc (TELO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Telomir Pharmaceuticals Inc (TELO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Telomir Pharmaceuticals Inc (TELO) Cash Flow - TradingKey
Telomir Pharmaceuticals Inc (TELO) Balance Sheet - TradingKey
Telomir Pharmaceuticals Inc (TELO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Telomir Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals Inc (TELO) Income Statement - TradingKey
Telomir Pharmaceuticals Inc (TELO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
12 Health Care Stocks Moving In Tuesday's Intraday Session - Sahm
Andriy Mushak Net Worth (2026) - GuruFocus
TELO Q4 2025 Earnings: EPS Misses Estimates by Wide Margin as Pre-Revenue Biotech Reports No RevenueEarnings Power Value - DonanımHaber
Number of shareholders of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals (TELO) Slips 2.3% as Stock Tests Key Support LevelBullish Percent Index - dars.gov.et
Price to earnings forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:TELO) - TradingView
TELO Q4 2025 Earnings: Wider-Than-Expected Loss Reflects R&D InvestmentWeak Earnings Momentum - DonanımHaber
Price to sales forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Price to book forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Enterprise value to EBITDA forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals Inc (TELO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Telomir Pharmaceuticals, Inc. develops Telomir-Zn to target intracellular metal balance in cancer cells - Traders Union
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model - ACCESS Newswire
Telomir Pharmaceuticals Q4 2025 Earnings: EPS Misses Estimates Amid Pre-Revenue Development StageEarnings Sentiment Score - DonanımHaber
Telomir Pharmaceuticals Inc (TELO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Telomir Pharmaceuticals to advance Telomir-Zn into clinical development for triple-negative breast cancer - Traders Union
Telomir Pharmaceuticals, Inc.: Telomir-Zn reverses insulin resistance in 14 days in new study - Traders Union
Exclusive: Telomir Pharmaceuticals secures FDA nod for its breast cancer therapy to advance into human study - MSN
Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data - TipRanks
Telomir publishes preclinical data on diabetes treatment candidate By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Publishes Peer-Reviewed Data Showing Telomir-Zn Restores Insulin Sensitivity in Type 2 Diabetes Model – Minichart - Minichart
Telomir publishes preclinical data on diabetes treatment candidate - Investing.com
Telomir (NASDAQ: TELO) adds Telomir-Zn diabetes data to support FDA-cleared TNBC trial - Stock Titan
Experimental drug candidate reversed insulin resistance in 14 days — in fish - Stock Titan
Telomir Pharmaceuticals (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Pre‑Revenue Development StageSubscription Growth Report - newsline.com
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Despite Positive Stock Reaction - newsline.com
Telomir Pharmaceuticals, Inc. reveals promising anti-tumor impact with Telomir-Zn in prostate cancer study - Traders Union
Telomir Pharmaceuticals (TELO) CFO Andriy Mushak files initial Form 3 - Stock Titan
Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO - Investing.com UK
Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change - TipRanks
Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO By Investing.com - Investing.com Australia
Telomir PharmaceuticalsAlan Weichselbaum To Step Down As CFO Effective June 6, 2026SEC Filing - TradingView
Telomir Pharmaceuticals, Inc. Announces CFO Changes, Effective June 6, 2026 - marketscreener.com
Telomir Pharmaceuticals (NASDAQ: TELO) taps consultant as new fractional CFO - Stock Titan
Telomir Pharmaceuticals (TELO) Edges Lower Amid Consolidation Near SupportTrend Following Picks - newsline.com
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer - ACCESS Newswire
0.27%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):